【武田制药Orzeyful获FDA批准，用于治疗1型发作性睡病】武田制药旗下武田制药美国公司的Orzeyful片剂已获得美国食品药品管理局批准，成为首款通过靶向食欲素信号缺失来治疗成人1型发作性睡病全谱症状的药物。Orzeyful的疗效已在两项为期12周、安慰剂对照的研究中得到证实，共纳入273名成人患者。服用Orzeyful 2mg的患者与安慰剂组相比，日间清醒度有所改善，猝倒发作次数减少。Orzeyful已被建议纳入《管制物质法》进行排期管理，目前正等待美国缉毒局的最终决定。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.